Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Enoticumab||SAR15319|REGN421||DLL4 Antibody 6||Enoticumab (REGN421) is a monoclonal Dll4 antibody that inhibits Notch signaling, which may prevent Vegf induced angiogenesis (PMID: 26377940, PMID: 25724527).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovarian cancer||not applicable||Enoticumab||Phase I||Actionable||In a Phase I study, Enoticumab (REGN421) demonstrated safety and preliminary efficacy in ovarian cancer patients (PMID: 25724527).||25724527|
|Unknown unknown||Advanced Solid Tumor||not applicable||Enoticumab||Phase I||Actionable||In a Phase I trial, Enoticumab (REGN421) resulted in partial response in 3% (2/53) and stable disease in 30% (16/53) of patients with advanced solid tumors (PMID: 25724527).||25724527|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|